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The cyclophosphamide is used in cancer treatment. The aim of this study was evaluating the effect 
of different doses of this drug on male mice reproductive parameters. The cyclophosphamide was 
administered in the doses 100, 150, 200 e 250 mg.kg-1, intraperitoneal route, for six weeks. As a result, it 
was observed a decrease in body mass and a decrease in testicles and kidney’s weight, in all animals treated 
with cyclophosphamide. Only the groups that received the doses 100, 150 mg.kg-1 of cyclophosphamide 
were able to fertilize their females. There was higher incidence of post- implantation losses, reabsorptions 
and decrease in fetal viability in the group that received the dose of 150 mg.kg-1. It was observed a 
reduction in epididymis and liver’s weight of the animals treated with the doses 150, 200 e 250 mg.kg-1. 
Abnormal spermatozoa were found in the doses 200 e 250 mg.kg-1. Based on the methodology used and 
results obtained, it was concluded that the cyclophosphamide was toxic, considering the decrease in 
animal’s body mass and testicle’s weight; promoted hepatotoxicity and nephrotoxic effect; influenced 
in the animals spermatogenesis taking them to infertility and/or subfertility; decreased fetal viability, 
despite it didn’t cause significant malformations in the offspring.
Uniterms: Cyclophosphamide/effects. Cyclophosphamide/toxicity. Spermatogenesis/experimental study. 
Chemotherapeutics/adverse effects. Fertility/experimental study.
A ciclofosfamida é utilizada no tratamento de câncer. Este estudo visa avaliar os efeitos das diferentes 
doses do fármaco nos parâmetros reprodutivos de camundongos machos. A ciclofosfamida foi 
administrada nas doses de 100, 150, 200 e 250 mg kg-1, via intraperitoneal por seis semanas. Como 
resultado observou-se diminuição de massa corporal, redução no peso de testículos e rins em todos os 
animais tratados com a ciclofosfamida. Apenas os grupos que receberam as doses de 100 e 150 mg kg-1 do 
quimioterápico foram capazes de fertilizar as fêmeas. Houve maior incidência de perdas pós-implantação, 
reabsorção e diminuição da viabilidade fetal no grupo que recebeu a dose de 150 mg kg-1. Observou-se 
redução nos pesos dos epidídimos e fígado dos animais tratados com as doses de 150, 200 e 250 mg kg-1. 
Espermatozóides anômalos foram encontrados nas doses de 200 e 250mg kg-1. Com base na metodologia 
empregada e nos resultados obtidos, conclui-se que a ciclofosfamida foi tóxica considerando-se a redução 
de massa corporal e o peso dos testículos dos animais; promoveu hepatotoxicidade e efeito nefrotóxico; 
influenciou na espermatogênese dos animais de forma a levá-los a um estado de infertilidade e/ou 
subfertilidade; diminuiu viabilidade fetal, entretanto não causou malformações significativas na prole.
Unitermos: Ciclofosfamida/efeitos. Ciclofosfamida/toxicidade. Espermatogênese/estudo experimental. 
Quimioterápicos/efeitos adversos. Fertilidade/ estudo experimental. 
INTRODUCTION
The use of mutagenic, carcinogenic and cytotoxic 
agents in treatments for several types of cancer is parti-
cularly risky in men at reproductive age, and, possibly, it 
could lead to congenital malformation in the offspring. 
Some agents affect the fertility and other aspects of repro-
ductive functions, for instance, treatments with anticancer 
drugs, such as cyclophosphamide, have been associated 
with oligospermia, azoospermia, seminiferous tubular 
atrophy (Fairley et al., 1972; Schamberg et al., 1981; 
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Kelly et al., 1992) and increase in the levels of Follicle 
Stimulating Hormone (FSH) (Trasler et al., 1985). The 
cyclophosphamide is a nitrogenous mustard pertaining to 
the group of cytotoxic or cytostatic drugs, also known as 
antineoplastics (Bach, Strom, 1986). It integrates a sub-
group of substances named alkylating agents, which are 
effective against slow-growing tumors that damage cells 
at any phase of cellular growth. The alkylating agents have 
the propriety to become strong electrophiles, by means 
of formation of intermediate carbon ions or transition 
complexes with target-molecules, which could include 
guanines and other components of DNA (Allison, 2000).
This agent is relatively inert until the binding 
phosphorus-nitrogen is broken by means of metabolism 
catalyzed by hepatic enzymes of Cytochrome P450, which 
are responsible for the reaction of initial drug activation. 
The activation occurs when the inactive cyclophospha-
mide is metabolized by P450 oxidase enzymes, being 
transformed into 4-hydroxycyclophosphamide that ori-
ginates the aldophosphamide. The latter, by its time, is 
carried to other tissues, where it is converted into mustard 
phosphoramide (the effectively cytotoxic molecule) and 
acrolein, which is responsible for the adverse effects (Rang 
et al., 2007). 
In the tumoral cells, the aldophosphamide undergoes 
spontaneous cleavage, with production of phosphoramine 
mustard and acrolein, being the former responsible for 
antitumoral effects through the alkylation of tumoral cells 
DNA, resulting in the crosslink of nucleic acids chains or 
in the binding of a nucleic acid to a protein. These altera-
tions damage seriously the DNA molecule, resulting in the 
cellular death (Hardman, Limbird, 2003). The main action 
of cyclophosphamide occurs during the replication, when 
some parts of DNA are not paired and more susceptible 
to alkylating. The effects manifest themselves, however, 
during the S phase, causing a blockage in G2 and the sub-
sequent cellular death (Rang et al., 2007).
The drug is a strong immunodepressive, acting in the 
cells with high mitotic activity, inhibiting as the humoral 
immune response, as the cellular one (Bach, Strom, 1986). 
Since its introduction in the clinical use, which occurred 
in 1958 (Chaube et al., 1967), the cyclophosphamide has 
been utilized in the treatment of both, malignant neoplasias 
and non-malignant neoplasias, such as rheumatic arthritis, 
as well as immunodepressive agent before organs trans-
plantation (Anderson et al., 1995).
According to some authors (Fairley et al., 1972; 
Schamberg et al., 1981; Kelly et al., 1992) the cyclophos-
phamide induces alterations in human and rodent testicular 
functions, and promotes infertility. And, considering that 
the male partner contributes for a half of genetic informa-
tion for the developing offspring, he should be examined 
as the responsible for teratogenesis and adverse alterations 
in the offspring development (Anderson, 2005).
The cyclophosphamide was chosen for this study 
because it is very clinically utilized in treatments of on-
cologic patients, and also because it is associated with 
variable periods of infertility in humans (Trasler et al., 
1988). So, this present research had as purpose to evaluate 
the effects caused by cyclophosphamide administration, in 
different doses, on the reproductive development of male 
mice, as well as to evaluate the intrauterine growth and 
offspring malformations.
MATERIAL AND METHODS
Swiss mice (Mus musculus), being fifty males and 
one hundred females, sexually mature, with average 
weight of 30 g and coming from the Central Vivarium of 
the Biological Sciences Center of the State University of 
Londrina (Universidade Estadual de Londrina – UEL), 
were utilized for this study. The entire experiment was 
conducted according the norms of Ethics Committee in 
Animal Experimentation of UEL.
The animals were maintained separate, in cages 
of propylene with cap of zincified wire containing wood 
shavings, with water and rations freely. They passed by 
a three days period of acclimation in the sector vivarium, 
before treatment starting. During the experiment deve-
lopment, the animals were maintained in a controlled 
luminosity regimen, being utilized for that a photoperiod 
of 12 hours light/12 hours dark, with temperature around 
22 ±2 °C. After weighing, the males were distributed ran-
domly in five experimental groups (with ten animals every 
one), as described as follows: the control group received 
PBS 0.1 mL/10 g of body weight (b.w.) and the groups 
C100, C150, C300 and C250 received cyclophosphami-
de in the doses of 100 mg.kg-1 (b.w.), 150 mg.kg-1 (b.w.),
 200 mg.kg-1 (b.w.) and 250 mg.kg-1 (b.w.), respectively. 
The concentrations were defined according the lower and 
higher doses found in reviewed literature (Schimenti et al., 
1997; Fagundes et al., 2005), being chosen intermediate 
values between them.
The treatment was developed once a week, intrape-
ritoneally (i.p.), during six weeks to embrace, at least, one 
spermatogenic cycle that, in mice, has the duration of 35 
days (Adler, 2001). After the fifth treatment, every male 
was matched with two nullipara females. These animals 
remained together during a week, to enable the female 
passing a complete estral cycle joined to treated male.
The presence of vaginal “plug” indicated the star-
ting of pregnancy period counting, being considered as 
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Day 0. At 17th gestational day, the females were anes-
thetized by inhalation of ethylic ether, euthanized by 
cervical dislocation, and submitted to laparotomy for 
fetuses’ withdrawal and counting of implantation sites 
and present reabsorptions number. The placentas were 
weighed in order to calculate the placental index. The 
fetuses were measured, weighed and fixed in Bodian’s 
and Acetone solutions, for further analyses of visceral 
and skeletal malformations, respectively. The visceral 
analysis was done through the sectioning proposed by 
Barrow and Taylor (1969) for thorax and abdomen stu-
dy, and by the strategic sectioning proposed by Wilson 
(1965) for head study. The fetuses fixed in acetone were 
submitted to the technique of Alizarin red described 
by Staples and Schnell (1964), for the development 
of skeletal analysis. In this analysis, the fetuses were 
evaluated by detection of skull, sternum, vertebras, ribs, 
pelvis, clavicle, phalanges, metacarpus and metatarsus 
according to the method of Taylor (1986). The visceral 
and fetal skeleton examinations were developed under 
stereomicroscopic magnifier.
The males were anesthetized by inhalation of ethylic 
ether and euthanized by cervical dislocation 24 hours after 
the last treatment, in the sixth week. Their heart, lungs, kid-
neys, liver and reproductive organs (testicles and epididy-
mis) were removed and weighed and it was also developed 
the morphologic evaluation of spermatozoids contained 
in the epididymis, according methodology described by 
Wyrobek et al. (1983). The blades were prepared and stained 
with Shorr and 200 cells per animal were analyzed in optical 
microscopy using an amplification of x1000.
The statistical interpretation for parametric data was 
done through the ANOVA followed by Tukey test; and the 
data with non-parametric distribution were analyzed by 
Kruskal-Wallis and Dunn, using the statistical software 
“Instat”, with significance level of 5%.
RESULTS
The cyclophosphamide administered to adult 
male mice in concentration of 100 mg.kg-1, 150 mg.kg-1, 
200 mg.kg-1 and 250 mg.kg-1 lead to significant variation 
of body mass along the experiment, as compared to control 
group (Figure 1). 
At Table I, it is observed the mean weight of organs 
of mice submitted to treatment. There was a statistically 
significant decrease of testicular weight in all animals tre-
ated with cyclophosphamide. In the same way, there was a 
significant decrease in the epididymides and liver weight 
of animals from groups C150, C200 and C250. There were 
no significant differences for the heart and lung weights; 
however, it was observed a decrease in the kidneys weight 
of all animals treated with cyclophosphamide.
FIGURE 1 – Body mass variation in male mice treated with 
different concentrations of cyclophosphamide, for 6 weeks. 
Average values ±MSE*. C100 cyclophosphamide 100 mg.kg-1, 
C150 cyclophosphamide 150 mg.kg-1, C200 cyclophosphamide 
200 mg.kg-1, C250 cyclophosphamide 250 mg.kg-1 Test: 
ANOVA/Tukey; p<0.05. *MSE = Mean Standard Error
TABLE I – Evaluation of mean weight of organs, in grams, of male mice treated with different concentrations of cyclophosphamide.
Parameters Control (10) C100 (10) C150 (10) C200 (10) C250 (10)
Testicles1 0.228±0.0169 0.141±0.0091* 0.097±0.0094* 0.081±0.0082* 0.074±0.0042*
Epididymides2 0.086±0.0054 0.105±0.0427 0.057±0.0060* 0.049±0.0045* 0.050±0.0045*
Heart1 0.203±0.016 0.166±0.009 0.194±0.017 0.165±0.007 0.164±0.008
Kidney1 0.569±0.023 0.472±0.013* 0.465±0.017* 0.465±0.015* 0.449±0.035*
Lung1 0.278±0.020 0.249±0.029 0.261±0.024 0.303±0.042 0.234±0.028
Liver1 2.067±0.093 1.789±0.094 1.701±0.081* 1.779±0.080* 1.567±0.134*
C100 cyclophosphamide 100 mg.kg-1, C150 cyclophosphamide 150 mg.kg-1, C200 cyclophosphamide 200 mg.kg-1, C250 
cyclophosphamide 250 mg.kg-1. Numerals between brackets indicate the number of utilized animals. *Statistically significant 
difference (p<0.05). Mean values ±MSE. Tests: 1Anova/Tukey, 2Kruskal-Wallis and Dunn
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In the fertility parameter, only the animals of the 
control group, C100 and C150 achieved to fertilize their 
female partners, being the fertility rate of 100, 70 and 
30%, respectively. The morphological analysis of sper-
matozoids contained in the epididymides tail presented 
alterations in all groups treated with the chemotherapeutic, 
being observed a higher incidence in the higher doses of 
cyclophosphamide, C200 and C250 (Figure 2). In the 
anomalous spermatozoids, the following head alterations 
were observed: amorphous, double, insertion, flag and 
microcephalus; the following tail alterations: comma, 
broken, rolled, tail node, double.
The parameters that aimed to evaluate the genotoxi-
city of cyclophosphamide on the male gamete are shown 
at Table II. In the analysis of parameters related to embryo-
fetal development, it was observed that the numbers of 
implantations of groups C100 and C150 had a significant 
decrease respecting to control group. In the analysis of post-
implantation losses rate, it was observed higher incidence 
in group C150, as well as the analysis of reabsorption rate 
presented statistical difference for this same group. There 
was no statistically significant difference for the variables 
fetal length, fetal weight and placental index. Respecting 
to fetal viability, it was only observed statistical difference 
in the C150 treatment group. In the visceral analysis, only 
two malformations were observed: a fetus with absence of 
left eye in the control group and a fetus with gastroschisis 
in group C150. Besides, in the skeletal analysis, sternebrae 
were observed in butterfly shape, asymmetric, reduced and 
with bipartite ossification in the control, C100 and C150. 
However, these malformations occurred in isolated manner; 
therefore, they are not statistically significant.
DISCUSSION
In this study, it was investigated the toxicity of an-
tineoplastic agent cyclophosphamide in adult male mice. 
The identification of cyclophosphamide effects on the ger-
minative cells could help to clarify the mechanisms invol-
ved in the male infertility mediated by this drug toxicity.
The results have shown significant weight decrease 
of mice treated with cyclophosphamide, indicating that 
doses of 100, 150, 200 and 250 mg.kg-1 were toxic for 
these animals. According to Manson, Kang (1994) and 
Chahoud et al. (1999), the body weight alterations are 
a usually observed indicative of toxicity in mice. It was 
verified also that the drug in high concentrations (200 
and 250 mg.kg-1) become the animals infertile, because 
the fertility rate of males in these groups was null. The 
effect of cyclophosphamide on fertility could be explained 
by the results obtained by Freire et al. (2006), according 
which the chemotherapeutic induces damage to DNA of 
germinative cells, and some of these cells are removed by 
apoptosis, resulting in decrease of mature spermatozoids 
(oligospermia or azoospermia). Camargo et al. (2006), 
have also concluded that cyclophosphamide is a strong 
TABLE - II – Evaluation of parameters related to fetal development of male mice offspring treated with cyclophosphamide
Parameters Control C100 C150 C200 C250
Number of implantations 10.500±0.817 7.357±0.767* 4.857±1.100* 0 0
Fetal viability (%) 64.416±5.089 47.119±9.992 36.918±8.758* 0 0
Rate of post-implantation losses (%) 35.584±5.089 56.022±9.819 63.082±8.758* 0 0
Rate of reabsorption (%) 34.708±5.069 47.578±9.642 63.082±8.758* 0 0
Fetal length (cm) 2.632±0.030 2.546±0.069 2.618±0.043 0 0
Fetal weight (g) 0.998±0.021 1.076±0.042 1.095±0.075 0 0
Placental index 0.102±0.0548 0.111±0.0992 0.118±0.0346 0 0
C100 cyclophosphamide 100 mg.kg-1, C150 cyclophosphamide 150 mg.kg-1, C200 cyclophosphamide 200 mg.kg-1, C250 
cyclophosphamide 250 mg.kg-1. *Statistically significant difference (p<0.05). Mean values ±MSE
FIGURE 2 – Rate of abnormal spermatozoids in every 
experimental and control group. C100 cyclophosphamide 
100 mg.kg-1, C150 cyclophosphamide 150 mg.kg-1, C200 
cyclophosphamide 200 mg.kg-1, C250 cyclophosphamide 
250 mg.kg-1
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agent promoter of infertility in mammalian, maintaining 
the individual infertile for a long post-treatment period or, 
in some cases, permanently, depending on both, the utili-
zed dosage and exposition time do drug. The results of this 
research have shown that the risk for infertility was higher, 
in treatments with high doses of cyclophosphamide; which 
is consistent with Kenney et al. (2001), whom observed 
preservation of gonadal functions in patients receiving 
lower doses of the chemotherapeutic.
The low incidence of malformations resulting from 
applied doses in this study is at variance with some works 
in the literature, in which the alkylating agent cyclophos-
phamide is able to cause malformations in mice embryos 
(Hales, 1989; Kitchin et al., 1986), altering the intrauterine 
development. Kelly et al. (1992), have also demonstrated 
that the treatment in rats with low dose of the drug, during 
four weeks, increased the post-implantations losses and 
fetus death. Aguilar-Mahecha et al. (2002), have demons-
trated that the exposition to this drug results in damage 
to male genome and induces hereditary mutations in the 
germinative lineage, leading to malformations. The results 
of this study that are discrepant with literature data could, 
probably, be due to possibility that administered doses had 
altered the fertility rate and spermatozoids quality. Howe-
ver, those spermatozoids achieving female fertilization 
resulted in fetuses with normal development.
Respecting to spermatozoids morphology, the 
treatment has shown that as the cyclophosphamide dose 
was increased, the rate of anomalous spermatozoids also 
increased. This could be explained by the fact that cyclo-
phosphamide induces an abnormal spermatogenesis, and 
could, in some way, alter the spermatozoids development, 
producing so alterations on them (Schimenti et al., 1997).
All the groups treated with the chemotherapeutic 
presented testicular weight decrease; however, this effect 
was more accentuated in animals treated with higher do-
ses (200 and 250 mg.kg-1). In the same way, there was a 
statistically significant decrease in the epididymides wei-
ght of animals from groups treated with concentration of 
150, 200 and 250 mg.kg-1, as compared to control group. 
These results are in accordance with study developed 
by Kaur et al. (1997), whom observed a decrease in the 
weight testicles and epididymis tail, besides a decrease 
in the spermatic counting, motility and viability of sper-
matozoids, in response to cyclophosphamide treatment. 
Considering the differences in the numbers of implanta-
tions between the different study experimental groups, it 
is supposed that cyclophosphamide in the utilized doses 
effectively influenced the animals spermatogenesis, 
leading them to a state of infertility or subfertility. The 
interference of chemotherapeutic during the spermatoge-
nesis process was evidenced through the morphological 
alterations found in spermatozoids of animals treated 
with the drug. These same alterations were observed in 
the studies of Vigi and Bustos-Obregon (1985), which 
showed occurrence of infertility associated to gametes 
malformations in animals treated with high doses of the 
chemotherapeutic.
It was observed significant decrease in the fetal via-
bility, with the dose of 150 mg.kg-1, respecting to control 
treatment, resulting in a higher index of post-implantation 
losses and reabsorption rate. This result suggests that cyclo-
phosphamide could cause damages to developing fetuses, 
leading them to death. It is clear that cyclophosphamide, 
in the doses utilized in this study, decreased the fertility of 
animals and influenced also in the number of implantations. 
Data respecting the negative effects of cyclophosphamide 
on intrauterine development, such as presence of congenital 
malformations, toxicity and mutagenicity, are described in 
the literature by Porter and Singh (1988).
The hepatotoxicity observed in this present study 
after administration of cyclophosphamide, is related with 
production of two metabolites, 4-hydroxycyclophospha-
mide and acrolein (DeLeve et al., 1996). In the same way, 
George et al. (2003) observed in their study that exposition 
to toxic metabolites of cyclophosphamide leads to increase 
in liver toxicity and mortality, decreasing so the patients’ 
survival.
The cyclophosphamide affects also the kidneys, pro-
moting lesions, sometimes irreversible. The renal toxicity 
observed in this present study is related to nephrotoxic and/
or vesical toxic effect of the drug, as reported by Costa et 
al. (2004). According to Antunes & Bianchi (2004), the 
nephrotoxicity is one of the main side-effects of therapy 
with cisplatin, an antineoplastic drug as well as cyclophos-
phamide. Based on employed methodology and obtained 
results, it is possible to conclude that cyclophosphamide 
leads to a decrease in body weight and testicles weight, 
in all administered concentrations, at doses of 150, 200 
and 250 mg.kg-1; it decreases also epididymides and liver 
weights; alters the morphology of spermatozoids com-
promising so the fertilization; presents toxicity for liver 
and kidneys and, in addition, decreases fetal viability 
increasing so the reabsorption rate; however, this chemo-
therapeutic didn’t cause significant malformations in the 
offspring of treated males.
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